Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 known ✓ | P22748 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene Glycol SCHEMBL9640310 | 0.95 | — | — | |
| SCHEMBL917184 | 0.89 | CA4 (0.35) | CA4 | |
| SCHEMBL2319007 | 0.87 | CA4 (0.39) | CA4 | |
| SCHEMBL15251307 | 0.87 | CA4 (0.34) | CA4 | |
| SCHEMBL6310261 | 0.85 | CA4 (0.35) | CA4 | |
| Potassium Ion SCHEMBL18173761 | 0.85 | CA12 (0.32) | CA4 | |
| SCHEMBL4398018 | 0.85 | CA4 (0.31) | CA4 | |
| Ammonia Solution, Strong SCHEMBL10493453 | 0.83 | CA4 (0.34) | CA4 | |
| SCHEMBL3765845 | 0.83 | CA4 (0.30) | CA4 | |
| SCHEMBL221253 | 0.82 | ALDH1A1 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3297627-A1 | HEALING COMPOSITION BASED ON SEDUM TELEPHIUM AND ALLANTOIN | Mag S.r.L. Societa' A Responsabilita' Limitata Semplificata (IT) | 2018-03-28 | — | — | EP | claimed |
| WO-2016188919-A1 | HEALING COMPOSITION BASED ON SEDUM TELEPHIUM AND ALLANTOIN | MAG S.R.L. SOCIETA' A RESPONSABILITA' LIMITATA SEMPLIFICATA (IT) | 2016-12-01 | — | — | WO | claimed |
| US-5846919-A | Rapid ophthalmic disinfection solution using salt and glycol and/or lower alkanol and surfactant | CIBA VISION CORPORATION (US) | 1998-12-08 | — | — | US | claimed |
| US-20220125056-A1 | TEMPLATED ANTIMICROBIAL MICROGELS AND METHODS OF MAKING AND USING THE SAME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS | 2022-04-28 | — | — | US | disclosed |
| WO-2020163462-A1 | TEMPLATED ANTIMICROBIAL MICROGELS AND METHODS OF MAKING AND USING THE SAME | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (US) | 2020-08-13 | — | — | WO | disclosed |
| EP-3297627-A1 | HEALING COMPOSITION BASED ON SEDUM TELEPHIUM AND ALLANTOIN | Mag S.r.L. Societa' A Responsabilita' Limitata Semplificata (IT) | 2018-03-28 | — | — | EP | disclosed |
| WO-2016188919-A1 | HEALING COMPOSITION BASED ON SEDUM TELEPHIUM AND ALLANTOIN | MAG S.R.L. SOCIETA' A RESPONSABILITA' LIMITATA SEMPLIFICATA (IT) | 2016-12-01 | — | — | WO | disclosed |
| US-20150297738-A1 | CONJUGATES COMPRISING HYDROXYALKYL STARCH AND A CYTOTOXIC AGENT AND PROCESS FOR THEIR PREPARATION | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2015-10-22 | — | — | US | disclosed |
| US-20150168618-A1 | INFRARED SHIELDING BODY | Konica Minolta, Inc. (JP) | 2015-06-18 | — | — | US | disclosed |
| US-20140088298-A9 | CONJUGATES COMPRISING HYDROXYALKYL STARCH AND A CYTOTOXIC AGENT AND PROCESS FOR THEIR PREPARATION | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2014-03-27 | — | — | US | disclosed |
| US-20140073778-A9 | CONJUGATES COMPRISING HYDROXYALKYL STARCH AND A CYTOTOXIC AGENT AND PROCESS FOR THEIR PREPARATION | FRESENIUS KABI DEUTSCHLAND GMBH (DE) | 2014-03-13 | — | — | US | disclosed |
| US-5001162-A | Use of avarone for the control of adult T-cell leukemia/lymphoma | MERZ + CO. GMBH & CO. (DE) | 1991-03-19 | — | — | US | disclosed |
| EP-0416678-A1 | Topical compositions containing Defibrotide | Crinos Industria Farmacobiologica S.p.A. (IT) | 1991-03-13 | — | — | EP | disclosed |
| US-4939178-A | Use of avarol for the control of adult T-cell leukemia/lymphoma | MERZ + CO. GMBH & CO. (DE) | 1990-07-03 | — | — | US | disclosed |
| US-4939177-A | Use of avarol for the control of AIDS and ARC | MERZ + CO. GMBH & CO. (DE) | 1990-07-03 | — | — | US | disclosed |
| WO-1990004650-A1 | A PURIFICATION PROCESS FOR COVALENTLY BOUND DNA/PROTEIN COMPLEXES | ROYAL FREE HOSPITAL SCHOOL OF MEDICINE (GB) | 1990-05-03 | — | — | WO | disclosed |
| EP-0252305-A2 | Use of avarone and avarol and derivatives thereof for the preparation of a pharmaceutical composition for the control of adult T-cell leukemia/lymphoma | Merz & Co. GmbH & Co. (DE) | 1988-01-13 | — | — | EP | disclosed |
| EP-0252304-A2 | Use of avarone and avarol and derivatives thereof for the preparation of a pharmaceutical composition for the control of AIDS and ARC | Merz & Co. GmbH & Co. (DE) | 1988-01-13 | — | — | EP | disclosed |
| US-4266024-A | USING ALKYLENEDIAMIDES, DIMETHYL SULFOXIDE OR GLUCOCORTICOIDS AS STIMULATORS FOR LYMPHOID CELLS | BOEHRINGER INGELHEIM GMBH (DE) | 1981-05-05 | — | — | US | disclosed |
| US-4108521-A | Method of making a display panel and the anodes therefor | BURROUGHS CORPORATION (US) | 1978-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140088298-A9 | CONJUGATES COMPRISING HYDROXYALKYL STARCH AND A CYTOTOXIC AGENT AND PROCESS FOR THEIR PREPARATION | HACL2, HASPIN, LIPA | CA4 2235/4885 |
| US-20220125056-A1 | TEMPLATED ANTIMICROBIAL MICROGELS AND METHODS OF MAKING AND USING THE SAME | MGAM, CD14, CD68 | CA4 364/4885 |
| US-20150297738-A1 | CONJUGATES COMPRISING HYDROXYALKYL STARCH AND A CYTOTOXIC AGENT AND PROCESS FOR THEIR PREPARATION | HASPIN, HACL2, PCNA | CA4 2426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.